Research programme: G protein-coupled receptor modulators - ASINEX/Biovitrum

Drug Profile

Research programme: G protein-coupled receptor modulators - ASINEX/Biovitrum

Alternative Names: Metabolic disorders therapeutics - ASINEX/Biovitrum

Latest Information Update: 09 Mar 2009

Price : $50

At a glance

  • Originator ASINEX; Biovitrum
  • Class
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 09 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top